Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-07-19

Clinical Trial Update: Steroid-reducing Effects of Crisaborole [Phase 4]

View source ↗

Summary

Phase 4 trial results indicate crisaborole may have steroid-sparing effects in atopic dermatitis, with results posted on July 19, 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Crisaborole (crisaborole)

Snippet

Sponsor: Johns Hopkins University | Conditions: Atopic Dermatitis, Eczema | Phase 4 | Status: COMPLETED | Results posted: 2024-07-19